News
AstraZeneca revealed its experimental breast cancer drug did not succeed in prolonging the survival of patients with the disease. Britain's largest pharmaceutical business said the trial focused ...
Hosted on MSN9mon
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial - MSNKey Takeaways A breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial.The trial ...
(Sharecast News) - AstraZeneca updated the market on two ongoing drug trials on Monday, with a key trial in breast cancer failing to improve survival. The FTSE 100 pharmaceutical giant said the ...
Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator’s choice of chemotherapy.
AstraZeneca lung cancer therapy Imfinzi fails in late-stage trial Jun. 25, 2024 10:24 AM ET AstraZeneca PLC (AZN) Stock By: Dulan Lokuwithana , SA News Editor 1 Comment Play ( 1min ) ...
AstraZeneca breast cancer drug trial fails to extend lives of patients. Britain's largest pharma firm said drug did not 'achieve statistical significance' ...
AstraZeneca revealed its experimental breast cancer drug did not succeed in prolonging the survival of patients with the disease. Britain's largest pharmaceutical business said the trial focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback